European CHMP recommends approval of use of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in a wider age group

Caplacizumab is currently licensed for the treatment of adults experiencing an episode of aTTP, in conjunction with plasma exchange and immunosuppression. The CHMP has issued a positive opinion, recommending that use be extended to adolescents aged ≥12 years weighing ≥40kg.


European Medicines Agency